Name: Future Research Needs to Reduce the Risk of Primary Breast Cancer in Women: Future Research Needs Paper Number 5 (en Inglés)
Price: 19.40 USD
Availability: InStock
Author: And Quality, Agency for Healthcare Resea ; Human Services, U. S. Department of Heal
ISBN: 9781489501875

portada Future Research Needs to Reduce the Risk of Primary Breast Cancer in Women: Future Research Needs Paper Number 5 (en Inglés)

Future Research Needs to Reduce the Risk of Primary Breast Cancer in Women: Future Research Needs Paper Number 5 (en Inglés)

Formato

Libro Físico

Autor

U. S. Department of Heal Human Services

Agency for Healthcare Resea And Quality

Editorial

Createspace

Idioma

Inglés

N° páginas

118

Encuadernación

Tapa Blanda

Dimensiones

28.0 x 21.6 x 0.6 cm

Peso

0.29 kg.

ISBN13

9781489501875

Categorías

Investigación médica

Future Research Needs to Reduce the Risk of Primary Breast Cancer in Women: Future Research Needs Paper Number 5 (en Inglés)

U. S. Department of Heal Human Services (Autor) · Agency for Healthcare Resea And Quality (Autor) · Createspace · Tapa Blanda

Libro Nuevo Origen: Estados Unidos

Envío Rápido

$ 21.99$ 19.40

-12%

Libro Nuevo

Quedan más de 100 unidades

$ 19.40

Llega entre el 23 Jun y el 26 Jun a FL. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Future Research Needs to Reduce the Risk of Primary Breast Cancer in Women: Future Research Needs Paper Number 5 (en Inglés)"

Breast cancer is the second most commonly diagnosed cancer in women in the United States, with over 200,000 new cases of invasive breast cancer expected in women in 2010. It is the second most common cause of cancer-related death in women, killing over 40,000 women each year. Tamoxifen was approved by the U.S. Food and Drug Administration (FDA) in 1999 as a preventive strategy for women at high risk of developing breast cancer. Data from the 2000 National Health Interview Survey estimated that 10 million U.S. women ages 35 to 79 years of age were candidates for tamoxifen preventive therapy and for 2.4 million of these women, the benefits would outweigh the harms. However, despite its approval for more than a decade, less than one percent of women use tamoxifen as a preventive therapy. In 2007, the FDA approved the use of raloxifene hydrochloride for reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis and/or at high risk for invasive breast cancer. In 2008, the Agency for Healthcare Research and Quality (AHRQ) commissioned the Oregon Evidence-based Practice Center (Oregon EPC) to conduct a comparative effectiveness review (CER) on the effectiveness of medications to reduce the risk of primary breast cancer in women. Briefly, the five key questions addressed by the review were: (1) In adult women without preexisting breast cancer, what is the comparative effectiveness of selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene, and the selective tissue estrogenic activity regulator (STEAR) tibolone, when used to reduce risk for primary breast cancer on improving short-term and long-term outcomes? (2) What is the evidence for harms? (3) How do outcomes vary by heterogeneity in subpopulations? (4) What is the evidence that harms or secondary potential benefits affect treatment choice, concordance, adherence, and persistence to treatment? (5) What methods, such as clinical risk-assessment models, have been used to identify women who could benefit from medications to reduce risk of breast cancer?

Opiniones del libro

¿Leíste este libro? Inicia sesión para poder agregar tu propia evaluación.

Ver más opiniones de clientes

0% (0)
0% (0)
0% (0)
0% (0)
0% (0)

Preguntas y respuestas sobre el libro

¿Tienes una pregunta sobre el libro? Inicia sesión para poder agregar tu propia pregunta.

Opiniones sobre Buscalibre

Ver más opiniones de clientes

Future Research Needs to Reduce the Risk of Primary Breast Cancer in Women: Future Research Needs Paper Number 5 (en Inglés) - And Quality, Agency for Healthcare Resea ; Human Services, U. S. Department of Heal

Reseña del libro "Future Research Needs to Reduce the Risk of Primary Breast Cancer in Women: Future Research Needs Paper Number 5 (en Inglés)"

Opiniones del libro

Preguntas frecuentes sobre el libro

¿El libro es original?

¿En qué Idioma está escrito el libro?

¿Cuál es la encuadernación de este libro?

Preguntas y respuestas sobre el libro

Opiniones sobre Buscalibre